The efficacy and safety of ethyl methyl hydroxypyridine succinate used as part of sequential therapy in patients with chronic cerebral ischemia

Objective: to investigate the efficacy and safety of Mexidol® FORTE 250 in patients with chronic cerebral ischemia (CCI) in the presence of hypertension and atherosclerosis.
Patients and methods. The investigation enrolled 20 patients aged 45 to 75 years with CCI in the presence of hypertension and atherosclerosis, who received intravenous Mexidol® administered dropwise at a dose of 500 mg once a day for 14 days, followed by oral Mexidol® FORTE 250 mg thrice a day for 60 days (a study group). A control group consisted of 14 patients with CCI in the presence of hypertension concurrent with atherosclerosis, who were prescribed combination therapy for CCI without using these drugs. The patients were examined before and at 14 and 60 days of treatment. The investigators studied subjective complaints, neurological symptoms, and the indicators of the Tinetti Performance-Oriented Mobility Assessment in Elderly Patients; the Montreal Cognitive Assessment (MoCA); the Hamilton Anxiety Rating Scale (HARS); asthenia rating scales (Multidimensional Fatigue Inventory, MFI-20); and the Clinical Global Impression (CGI) scale over time.
Results and discussion. Therapy with Mexidol® in patients with CCI in the presence of hypertension and atherosclerosis was found to be accompanied by positive changes in the asthenia rating scale MFI-20, cognitive functions assessed by MoCA, as well as Tinetti movement coordination. No significant differences in these indicators were noted in patients of the control group. Combination treatment for CCI with Mexidol®and Mexidol® FORTE 250 as a sequential therapy was twice more effective than that without using these drugs, as shown by the scales as a whole and it was up to 10 times greater for individual scale parameters. 
Conclusion. The study of Mexidol® FORTE 250 as part of the sequential therapy, which was used according to the above regimen, indicates its clinical efficacy and safety in patients with CCI.

chronic cerebral ischemia, cognitive and motor functions, asthenic and anxiety-depressive disorders, Mexidol® FORTE 250

1. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2014. 224 p.

2. Parfenov VA. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psichosomatics. 2019;11(3S):61-7. (In Russ.) doi: 10.14412/2074-2711-2019-3S-61-67

3. Lokshina AB, Zakharov VV. Voprosy terapii khronicheskoi ishemii golovnogo mozga. Nevrologiya. 2017; (3):14-8.

4. Voskresenskaya ON, Zakharova NB, Tarasova YuS, et al. Possible mechanisms of cognitive dysfunction in patients with chronic forms of cerebrovascular diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psichosomatics. 2018;10(1): 32-6. (In Russ.). doi: 10.14412/2074-2711-2018-1-32-36.

5. Kamchatnov PR, Umarova KhYa. Chronic ischemia of the brain: opportunities for therapy. Spravochnik poliklinicheskogo vracha. 2013;(6):3-7. (In Russ.).

6. Gusev EI, Chukanova EI, Chukanova AS. Khronicheskaya tserebrovaskulyarnaya nedostatochnost' [Chronic cerebrovascular insufficiency]. Moscow: Meditsina; 2019. 190 p.

7. Putilina MV. Chronic brain ischemia. Nevrologiya i neirokhirurgiya. 2012;(4):7-12. (In Russ.).

8. Chukanova EI, Chukanova AS. Efficacy and safety of Mexidol FORTE 250 in sequential therapy in patients with chronic brain ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.).

9. Kashin AV. Efficacy and safety of Mexidol in the treatment of cognitive dysfunction in patients with ischemic stroke. Byulleten' eksperimental'noi biologii i meditsiny. 2012;(Suppl. 1):36–8. (In Russ.).

10. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double-blind multicenter placebo-controlled parallel group study of the efficacy and safety of Mexidol in long-term sequential therapy in patients with acute and early recovery periods of hemispheric ischemic stroke (EPICA). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017; 117(3-2):55-65. (In Russ.).

11. Boiko AN, Lebedeva AV, Shchukin IA, et al. Possibilities of medical correction of moderate cognitive disorder. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113(2):28-32. (In Russ.).

12. Voronina TA. Mexidol: spectrum of pharmacological effects. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112(12):86-90. (In Russ.).

13. Bolotova EV, Lushpai TYu, Kovrigina IV. Improving the effectiveness of treatment of hypertensive encephalopathy with Mexidol. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(4):61-4. (In Russ.).

14. Tsoi KK, Chan JY, Hirai HW, et al. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2015 Sep;175(9):1450-8. doi: 10.1001/jamainternmed.2015.2152.

15. Smets EM, Garssen BJ, Bonke B, DeHaes JC. The Multidimensional fatigue inventory (MFI) psychometric properties of an instrument to assess fatigue. J Psychosom Res. 1995 Apr;39(3):315-25.

16. Borovikov VP, Ivchenko GI. Uchebnik po matematicheskoi statistike s uprazhneniyami v sisteme Statistica [Textbook on mathematical statistics with exercises in the Statistica system]. Moscow: StatSoft; 2003. 368 p.

17. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Sep; 42(9):2672-713. doi: 10.1161/STR. 0b013e3182299496. Epub 2011 Jul 21.